Andere Sprachen Beam Therapeutics Inc.

Aktien

A2PY7P

US07373V1052

BEAM

Markt geschlossen - Nasdaq Andere Börsenplätze 22:00:00 25.04.2024			% 5 Tage	% 1. Jan.
21.6 ^USD	-5.01%		-11.15%	-20.65%

04.04.	Beam Therapeutics Insider verkaufte Aktien im Wert von $581,617, laut einer aktuellen SEC Einreichung	MT
04.04.	Beam Therapeutics Insider verkaufte Aktien im Wert von $734.805, laut einer aktuellen SEC Einreichung	MT

Andere Sprachen

Erhalten Sie Zugang zu allen Nachrichten über alle Unternehmen: Verpassen Sie keine profitable Anlagechance mehr!

100% kostenlose Registrierung

Beam Therapeutics Insider Sold Shares Worth $581,617, According to a Recent SEC Filing	04.04.
Beam Therapeutics Insider Sold Shares Worth $734,805, According to a Recent SEC Filing	04.04.
Beam Therapeutics Says BEAM-302 Drug Candidate Gets UK Clearance for Alpha-1 Antitrypsin Deficiency	26.03.
Beam Therapeutics Announces Clearance of Clinical Trial Authorisation Application for BEAM-302 for the Treatment of Alpha-1 Antitrypsin Deficiency (AATD)	26.03.
Beam Therapeutics Announces Clearance of Clinical Trial Authorisation Application for BEAM-302 for the Treatment of Alpha-1 Antitrypsin Deficiency (AATD)	26.03.
Beam Therapeutics Inc. Announces Clearance of Clinical Trial Authorisation Application for BEAM-302 for the Treatment of Alpha-1 Antitrypsin Deficiency	26.03.
Beam Therapeutics to Participate in Upcoming March 2024 Investor Conferences	28.02.
Beam Therapeutics to Participate in Upcoming March 2024 Investor Conferences	28.02.
Health Care Down as Viking Move Rattles Novo Shares -- Health Care Roundup	27.02.
Beam Therapeutics Shares Jump on Surprise Q4 Profit	27.02.
Beam Therapeutics Reports Surprise Q4 Profit; Shares Jump in Early Trading	27.02.
Beam Therapeutics Reports Fourth Quarter and Year-End 2023 Financial Results and Reiterates Anticipated Milestones	27.02.
Beam Therapeutics Inc. Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2023	27.02.
Beam Therapeutics to Participate in the Guggenheim Healthcare Talks 6th Annual Biotechnology Conference	05.02.
Beam Therapeutics to Participate in the Guggenheim Healthcare Talks 6th Annual Biotechnology Conference	05.02.
Beam CEO Andy Bromberg: Bitcoin ETFs a financialisation away from the original essence of crypto	30.01.
North American Morning Briefing : Microsoft Kicks -2-	30.01.
Beam Therapeutics Shares Gain Following JPMorgan's Upgrade to Overweight	29.01.
Rapport Therapeutics Appoints Terry-Ann Burrell to Board of Directors	17.01.
Beam Therapeutics Highlights Progress Across Base Editing Portfolio and Outlines 2024 Anticipated Milestones	08.01.

Keine Ergebnisse zu dieser Suche

Alle Nachrichten Analystenempfehlungen Wichtige Fakten Insiders Transkripte Pressemitteilungen Offizielle Publikationen Andere Sprachen Trading-Ideen MarketScreener Artikel MarketScreener Analysen

Filter

Schlagzeilen

Bitcoin ETFs sind großartig, aber keine echte Kryptowährung: Beam CEO

Am 30. Januar 2024 um 20:21 Uhr